Inicio Estudios Efficient Non-Viral Gene Modification of Mesenchymal Stromal Cells from Umbilical Cord Wharton¿s Jelly with Polyethylenimine

Efficient Non-Viral Gene Modification of Mesenchymal Stromal Cells from Umbilical Cord Wharton¿s Jelly with Polyethylenimine

Fecha de publicación: 
Viernes, Junio 18, 2021
Descripción: 

Mesenchymal stromal cells (MSC) derived from human umbilical cord Wharton’s jelly (WJ) have a wide therapeutic potential in cell therapy and tissue engineering because of their multipotential capacity, which can be reinforced through gene therapy in order to modulate specific responses. However, reported methodologies to transfect WJ-MSC using cationic polymers are scarce. Here, WJ-MSC were transfected using 25 kDa branched- polyethylenimine (PEI) and a DNA plasmid encoding GFP. PEI/plasmid complexes were characterized to establish the best transfection efficiencies with lowest toxicity. Expression of MSC-related cell surface markers was evaluated. Likewise, immunomodulatory activity and multipotential capacity of transfected WJ-MSC were assessed by CD2/CD3/CD28-activated peripheral blood mononuclear cells (PBMC) cocultures and osteogenic and adipogenic differentiation assays, respectively. An association between cell number, PEI and DNA content, and transfection efficiency was observed. The highest transfection efficiency (15.3 ± 8.6%) at the lowest toxicity was achieved using 2 ng/μL DNA and 3.6 ng/μL PEI with 45,000 WJ-MSC in a 24-well plate format (200 μL). Under these conditions, there was no significant difference between the expression of MSC-identity markers, inhibitory effect on CD3+ T lymphocytes proliferation and osteogenic/adipogenic differentiation ability of transfected WJ-MSC, as compared with non-transfected cells. These results suggest that the functional properties of WJ-MSC were not altered after optimized transfection with PEI. View Full-Text

Tipo de estudio: 
Artículo
Número de páginas: 
19
Entidad: 
I.D. de Ciencia, Biotecnológia e Innovación en Salud
Dependencia(s): 
Dirección Gestión de Conocimiento
Fuente de financiación: 
Sistema General de Regalías BPIN (2012000100186) and Fondo Financiero Distrital de Salud (FFDS) Convenio 0101 de 2017 y Convenio 607 de 2017- 681577758114
Fuente de información: 
Unidad de Terapias Avanzadas - IDCBIS
icono de link

Información adicional

Política pública relacionada: 
Documento CONPES 3582 de 2009, “Política Nacional de Ciencia, Tecnología e Innovación"
Relación con el Plan Distrital de Desarrollo: 
Plan Distrital de Desarrollo Bogotá Mejor Para Todos 2016 - 2020